Literature DB >> 18768944

Prognostic importance of defibrillator shocks in patients with heart failure.

Jeanne E Poole1, George W Johnson, Anne S Hellkamp, Jill Anderson, David J Callans, Merritt H Raitt, Ramakota K Reddy, Francis E Marchlinski, Raymond Yee, Thomas Guarnieri, Mario Talajic, David J Wilber, Daniel P Fishbein, Douglas L Packer, Daniel B Mark, Kerry L Lee, Gust H Bardy.   

Abstract

BACKGROUND: Patients with heart failure who receive an implantable cardioverter-defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) may later receive therapeutic shocks from the ICD. Information about long-term prognosis after ICD therapy in such patients is limited.
METHODS: Of 829 patients with heart failure who were randomly assigned to ICD therapy, we implanted the ICD in 811. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate. All other ICD shocks were considered to be inappropriate.
RESULTS: Over a median follow-up period of 45.5 months, 269 patients (33.2%) received at least one ICD shock, with 128 patients receiving only appropriate shocks, 87 receiving only inappropriate shocks, and 54 receiving both types of shock. In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes (hazard ratio, 5.68; 95% confidence interval [CI], 3.97 to 8.12; P<0.001). An inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death (hazard ratio, 1.98; 95% CI, 1.29 to 3.05; P=0.002). For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated (hazard ratio, 2.99; 95% CI, 2.04 to 4.37; P<0.001). The most common cause of death among patients who received any ICD shock was progressive heart failure.
CONCLUSIONS: Among patients with heart failure in whom an ICD is implanted for primary prevention, those who receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks. 2008 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2008        PMID: 18768944      PMCID: PMC2922510          DOI: 10.1056/NEJMoa071098

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

2.  Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks.

Authors:  Can Hasdemir; Nayyar Shah; Arun P Rao; Helbert Acosta; Kagari Matsudaira; Barbara R Neas; Dwight W Reynolds; Sunny Po; Ralph Lazzara; Karen J Beckman
Journal:  J Cardiovasc Electrophysiol       Date:  2002-02

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.

Authors:  Karl Swedberg; Lars G Olsson; Andrew Charlesworth; John Cleland; Peter Hanrath; Michel Komajda; Marco Metra; Christian Torp-Pedersen; Philip Poole-Wilson
Journal:  Eur Heart J       Date:  2005-03-14       Impact factor: 29.983

5.  Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.

Authors:  Ilan Goldenberg; Arthur J Moss; W Jackson Hall; Scott McNitt; Wojciech Zareba; Mark L Andrews; David S Cannom
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

6.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

7.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

8.  The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function.

Authors:  W Tang; M H Weil; S Sun; H Yamaguchi; H P Povoas; A M Pernat; J Bisera
Journal:  J Am Coll Cardiol       Date:  1999-09       Impact factor: 24.094

9.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

10.  Myocardial dysfunction after electrical defibrillation.

Authors:  Hitoshi Yamaguchi; Max Weil; Wanchun Tang; Takashi Kamohara; Xiaohua Jin; Joe Bisera
Journal:  Resuscitation       Date:  2002-09       Impact factor: 5.262

View more
  304 in total

1.  A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data.

Authors:  Bryan C Wallace; Larry A Allen; Christopher E Knoepke; Russell E Glasgow; Carmen L Lewis; Diane L Fairclough; Laura J Helmkamp; Monica D Fitzgerald; Wendy S Tzou; Daniel B Kramer; Paul D Varosy; Sanjaya K Gupta; John M Mandrola; Scott C Brancato; Pamela N Peterson; Daniel D Matlock
Journal:  Am Heart J       Date:  2020-04-20       Impact factor: 4.749

Review 2.  The emerging role of cardiac resynchronization therapy in milder heart failure: are we implanting too late for response?

Authors:  Jason Bradfield; Noel G Boyle; Ravi Mandapati; Kalyanam Shivkumar
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 3.  Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

Review 4.  [Treatment of progressive heart failure: pharmacotherapy, resynchronization (CRT), surgery].

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Herz       Date:  2010-03       Impact factor: 1.443

5.  [ICD therapy for primary prevention. The patient in the early post-infarct phase].

Authors:  N C Ewertsen; G Steinbeck; J Senges; D Andresen
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

6.  [Is intraoperative ICD-testing still necessary?].

Authors:  C Mewis; H-R Neuberger; A Buob
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

7.  Arrhythmias: Catheter ablation for prevention of ventricular tachycardia.

Authors:  Usha B Tedrow; William G Stevenson
Journal:  Nat Rev Cardiol       Date:  2010-04       Impact factor: 32.419

8.  Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.

Authors:  Selcuk Adabag; Kristen K Patton; Alfred E Buxton; Thomas S Rector; Kristine E Ensrud; Kairav Vakil; Wayne C Levy; Jeanne E Poole
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

9.  Mitigating Post-Extraction Risk: Is it Worth the inVESTment?

Authors:  Mina K Chung
Journal:  JACC Clin Electrophysiol       Date:  2016-12-21

Review 10.  ICD programming to reduce shocks and improve outcomes.

Authors:  Valentina Kutyifa; Wojciech Zareba; Arthur J Moss
Journal:  Curr Cardiol Rep       Date:  2014       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.